+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Companion Diagnostics Market Market By Technology, By Indication, By End-user, Regional Outlook - Global Forecast up to 2030- Product Image
Companion Diagnostics Market Market By Technology, By Indication, By End-user, Regional Outlook - Global Forecast up to 2030- Product Image
Sale

Companion Diagnostics Market Market By Technology, By Indication, By End-user, Regional Outlook - Global Forecast up to 2030

  • PDF Icon

    Report

  • 146 Pages
  • July 2024
  • Region: Global
  • IHR Insights
  • ID: 4470729
UP TO OFF until Dec 31st 2024
10% Free customization
Description Jump to:
10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Therapeutic drugs are used in conjunction with a medical instrument known as a companion diagnostic to evaluate how well they function and how they impact a specific human body. Companion Diagnostics and medications are designed to either include or exclude patient groups according to the characteristics of how they react to treatment. This tool helps the doctor decide whether a particular therapeutic plan is best for the patient in the long run.

The FDA approved Roche's Cobas EGFR Mutation Test v2 companion diagnostic in 2021 for use with EGFR tyrosine kinase inhibitors to treat lung cancer. To determine which patients will respond to a therapeutic medication and which ones won't, a clinical test known as Companion Diagnostic (CDx) was developed in tandem with it. This is done to find out which patient groups the matching medication can or cannot treat. By employing CDx to support them in evaluating the benefits, risks, and side effects of therapeutic drugs, practitioners can guarantee patient safety.

These days, it's widely acknowledged that due to advances in genetics and genetic sequencing, different people react to drugs differently. Knowing a person's genetic characteristics, or "biomarkers," can help with the delivery of "the right drug, at the right time, at the right dose, for the right person." Pharmaceutical and biopharmaceutical businesses are always striving to implement patient-selection diagnostic frameworks at the early phases of drug development in order to provide targeted therapies to the right candidate. This contributes to the further expansion of the Companion Diagnostics market.

Companion Diagnostics Market Market based on Connectivity Technology:

  • Polymerase Chain Reaction
  • Immunohistochemistry
  • In-situ Hybridization
  • Next Generation Gene Sequencing
  • Others

Companion Diagnostics Market Market based on Indication:

  • Cancer
  • Neurological Diseases
  • Infectious Diseases
  • Others

Companion Diagnostics Market Market based on End-user:

  • Pharmaceutical & Biopharmaceutical Companies
  • Reference Laboratories
  • Contract Research Organizations (CROs)

Companion Diagnostics Market Market based on Geography:

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
  • Asia Pacific (APAC)
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
  • Latin America (LATAM)
  • Brazil
  • Argentina
  • Rest of South America
  • Middle East and Africa (MEA)
  • UAE
  • Turkey
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa
Companion diagnostic examinations (also known as CDXs) are thought to be crucial when opting to treat lung cancer with targeted medications. Patients with lung cancer who had Companion Diagnostics done as part of their initial treatment have longer survival rates than those who do not. Growth is anticipated to be driven worldwide by the high incidence rate of non-small cell lung cancer (NSCLC) and the growing number of oncology companion diagnostic tests for the illness.

The goal of NGS-based symptomatic diagnostics is to enable the use of atomic data from each patient's expanding genome to guide disease treatment choices. Cutting-edge sequencing finds several biomarkers for different pharmacological regimens faster than traditional sequencing approaches. Treatment for a wide range of illnesses may benefit from the use of NGS boards for biomarker testing in a single test. The numerous state-of-the-art advancements in NGS additionally provide market players with a quick benefit over rivals presenting alternative innovations including as PCR, ICH, and ISH. The majority of market rivals are focusing on creating companion demonstration items in light of NGS.

The goal of the next-generation sequencing-based companion diagnostic tests is to open nuclear information from each persistent development genome, thereby coordinating treatment decisions for disease drugs. Front-end sequencing identifies several biomarkers for a variety of drugs faster than other sequencing approaches. Treating a variety of illnesses may be made easier by using NGS sheets for biomarker testing in a single test. Additionally, market organizations benefit from a rapid advantage over rivals offering alternative methods such as PCR, ICH, and ISH because to the numerous inventive degrees of innovation in NGS. As a result, major industry participants are thinking about NGS but focusing on producing graphical items.

The product and service, technology, indication, end user, and region segmentation categories are used to divide the companion diagnostics market. The market is divided into three segments based on Product & Service: Assays, Kits & Reagents, and Software & Services. Moreover, the market is divided into Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry, and Other segments depending on technology. Additionally, the market is segmented into five categories based on indication: infectious diseases, cancer, neurological disorders, cardiovascular diseases, and other indications. The market is divided into four segments based on End Users: Contract Research Organizations, Reference Laboratories, Pharmaceutical & Biopharmaceutical Companies, and Other End Users. Furthermore, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa based on region.
  • This report illustrates the most vital attributes of the Companion Diagnostics Market Market, which are driving and providing opportunities.
  • This research gives an in-depth analysis of the Companion Diagnostics Market Market growth on the basis of several segments in the market.
  • This report presents the predictions of the past and present trends of the Companion Diagnostics Market Market.
  • This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Companion Diagnostics Market Market.

Table of Contents

1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Technology: Market Size & Analysis
5.1. Overview
5.2. Polymerase Chain Reaction
5.3. Immunohistochemistry
5.4. In-situ Hybridization
5.5. Next Generation Gene Sequencing
5.6. Others
6. Indication: Market Size & Analysis
6.1. Overview
6.2. Cancer
6.3. Neurological Diseases
6.4. Infectious Diseases
6.5. Others
7. End-user: Market Size & Analysis
7.1. Overview
7.2. Pharmaceutical & Biopharmaceutical Companies
7.3. Reference Laboratories
7.4. Contract Research Organizations (CROs)
8. Geography: Market Size & Analysis
8.1. Overview
8.2. North America (U.S., Mexico, Canada)
8.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
8.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
8.5. Latin America (Brazil, Argentina)
8.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
9. Competitive Landscape
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. Vendor Profiles
10.1. ARUP LABORATORIES
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. ROCHE MOLECULAR SYSTEMS INC.
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. DAKO INC.
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. QIAGEN LTD.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. BIOMÉRIEUX INC.
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. VENTANA MEDICAL SYSTEMS INC.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. ABBOTT MOLECULAR INC.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. MYRIAD GENETICS INC.
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. BIOGENEX LABORATORIES, INC.
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. THERMO FISHER SCIENTIFIC INC.
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. Analyst Opinion
12. Annexure
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
List of Tables
Table 1. Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 2. Companion Diagnostics Market Value for Polymerase Chain Reaction, by Geography, 2021-2030 (USD Billion)
Table 3. Companion Diagnostics Market Value for Immunohistochemistry, by Geography, 2021-2030 (USD Billion)
Table 4. Companion Diagnostics Market Value for In-Situ Hybridization, by Geography, 2021-2030 (USD Billion)
Table 5. Companion Diagnostics Market Value for Next Generation Gene Sequencing, by Geography, 2021-2030 (USD Billion)
Table 6. Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 7. Companion Diagnostics Market Value for Cancer, by Geography, 2021-2030 (USD Billion)
Table 8. Companion Diagnostics Market Value for Neurological Diseases, by Geography, 2021-2030 (USD Billion)
Table 9. Companion Diagnostics Market Value for Others, by Geography, 2021-2030 (USD Billion)
Table 10. Companion Diagnostics Market Value for Infectious Diseases, by Geography, 2021-2030 (USD Billion)
Table 11. Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 12. Companion Diagnostics Market Value for Pharmaceutical & Biopharmaceutical Companies, 2021-2030 (USD Billion)
Table 13. Companion Diagnostics Market Value for Reference Laboratories, by Geography, 2021-2030 (USD Billion)
Table 14. Companion Diagnostics Market Value for Contract Research Organizations (Cros), 2021-2030 (USD Billion)
Table 15. North America Companion Diagnostics Market Value, by Country, 2021-2030 (USD Billion)
Table 16. North America Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 17. North America Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 18. North America Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 19. U.S Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 20. U.S Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 21. U.S Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 22. Canada Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 23. Canada Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 24. Canada Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 25. Mexico Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 26. Mexico Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 27. Mexico Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 28. Europe Companion Diagnostics Market Value, by Country, 2021-2030 (USD Billion)
Table 29. Europe Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 30. Europe Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 31. Europe Companion Diagnostics Market Value, End Use Industries, 2021-2030 (USD Billion)
Table 32. Germany Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 33. Germany Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 34. Germany Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 35. U.K Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 36. U.K Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 37. U.K Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 38. France Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 39. France Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 40. France Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 41. Italy Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 42. Italy Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 43. Italy Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 44. Spain Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 45. Spain Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 46. Spain Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 47. Roe Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 48. Roe Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 49. Roe Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 50. Asia-Pacific Companion Diagnostics Market Value, by Country, 2021-2030 (USD Billion)
Table 51. Asia-Pacific Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 52. Asia-Pacific Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 53. Asia-Pacific Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 54. China Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 55. China Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 56. China Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 57. India Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 58. India Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 59. India Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 60. Japan Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 61. Japan Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 62. Japan Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 63. Rest of APAC Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 64. Rest of APAC Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 65. Rest of APAC Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 66. Latin America Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 67. Latin America Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 68. Latin America Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 69. Brazil Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 70. Brazil Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 71. Brazil Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 72. Argentina Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 73. Argentina Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 74. Argentina Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 75. Middle East and Africa Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 76. Middle East and Africa Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 77. Middle East and Africa Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 78. Saudi Arabia Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 79. Saudi Arabia Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 80. Saudi Arabia Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 81. Uae Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 82. Uae Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 83. Uae Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 84. Rest of Middle East and Africa Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Table 85. Rest of Middle East and Africa Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Table 86. Rest of Middle East and Africa Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Table 87. Arup Laboratories: Financials
Table 88. Arup Laboratories: Products & Services
Table 89. Arup Laboratories: Recent Developments
Table 90. Roche Molecular Systems Inc.: Financials
Table 91. Roche Molecular Systems Inc.: Products & Services
Table 92. Roche Molecular Systems Inc.: Recent Developments
Table 93. Dako Inc.: Financials
Table 94. Dako Inc.: Products & Services
Table 95. Dako Inc.: Recent Developments
Table 96. Qiagen Ltd.: Financials
Table 97. Qiagen Ltd.: Products & Services
Table 98. Qiagen Ltd.: Recent Developments
Table 99. Biomérieux Inc.: Financials
Table 100. Biomérieux Inc.: Products & Services
Table 101. Biomérieux Inc.: Recent Developments
Table 102. Ventana Medical Systems Inc.: Financials
Table 103. Ventana Medical Systems Inc.: Products & Services
Table 104. Ventana Medical Systems Inc.: Recent Developments
Table 105. Abbott Molecular Inc.: Financials
Table 106. Abbott Molecular Inc.: Products & Services
Table 107. Abbott Molecular Inc.: Developments
Table 108. Myriad Genetics Inc.: Financials
Table 109. Myriad Genetics Inc.: Products & Services
Table 110. Myriad Genetics Inc.: Recent Developments
Table 111. Biogenex Laboratories, Inc.: Financials
Table 112. Biogenex Laboratories, Inc.: Products & Services
Table 113. Biogenex Laboratories, Inc.: Recent Developments
Table 114. Thermo Fisher Scientific Inc.: Financials
Table 115. Thermo Fisher Scientific Inc.: Products & Services
Table 116. Thermo Fisher Scientific Inc.: Recent Developments
List of Figures
Chart. 1. Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 2. Companion Diagnostics Market Value for Polymerase Chain Reaction, by Geography, 2021-2030 (USD Billion)
Chart. 3. Companion Diagnostics Market Value for Immunohistochemistry, by Geography, 2021-2030 (USD Billion)
Chart. 4. Companion Diagnostics Market Value for In-Situ Hybridization, by Geography, 2021-2030 (USD Billion)
Chart. 5. Companion Diagnostics Market Value for Next Generation Gene Sequencing, by Geography, 2021-2030 (USD Billion)
Chart. 6. Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 7. Companion Diagnostics Market Value for Cancer, by Geography, 2021-2030 (USD Billion)
Chart. 8. Companion Diagnostics Market Value for Neurological Diseases, by Geography, 2021-2030 (USD Billion)
Chart. 9. Companion Diagnostics Market Value for Others, by Geography, 2021-2030 (USD Billion)
Chart. 10. Companion Diagnostics Market Value for Infectious Diseases, by Geography, 2021-2030 (USD Billion)
Chart. 11. Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 12. Companion Diagnostics Market Value for Pharmaceutical & Biopharmaceutical Companies, 2021-2030 (USD Billion)
Chart. 13. Companion Diagnostics Market Value for Reference Laboratories, by Geography, 2021-2030 (USD Billion)
Chart. 14. Companion Diagnostics Market Value for Contract Research Organizations (Cros), 2021-2030 (USD Billion)
Chart. 15. North America Companion Diagnostics Market Value, by Country, 2021-2030 (USD Billion)
Chart. 16. North America Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 17. North America Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 18. North America Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 19. U.S Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 20. U.S Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 21. U.S Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 22. Canada Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 23. Canada Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 24. Canada Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 25. Mexico Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 26. Mexico Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 27. Mexico Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 28. Europe Companion Diagnostics Market Value, by Country, 2021-2030 (USD Billion)
Chart. 29. Europe Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 30. Europe Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 31. Europe Companion Diagnostics Market Value, End Use Industries, 2021-2030 (USD Billion)
Chart. 32. Germany Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 33. Germany Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 34. Germany Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 35. U.K Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 36. U.K Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 37. U.K Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 38. France Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 39. France Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 40. France Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 41. Italy Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 42. Italy Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 43. Italy Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 44. Spain Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 45. Spain Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 46. Spain Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 47. Roe Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 48. Roe Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 49. Roe Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 50. Asia-Pacific Companion Diagnostics Market Value, by Country, 2021-2030 (USD Billion)
Chart. 51. Asia-Pacific Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 52. Asia-Pacific Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 53. Asia-Pacific Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 54. China Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 55. China Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 56. China Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 57. India Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 58. India Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 59. India Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 60. Japan Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 61. Japan Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 62. Japan Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 63. Rest of APAC Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 64. Rest of APAC Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 65. Rest of APAC Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 66. Latin America Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 67. Latin America Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 68. Latin America Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 69. Brazil Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 70. Brazil Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 71. Brazil Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 72. Argentina Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 73. Argentina Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 74. Argentina Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 75. Middle East and Africa Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 76. Middle East and Africa Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 77. Middle East and Africa Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 78. Saudi Arabia Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 79. Saudi Arabia Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 80. Saudi Arabia Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 81. Uae Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 82. Uae Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 83. Uae Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 84. Rest of Middle East and Africa Companion Diagnostics Market Value, by Technology, 2021-2030 (USD Billion)
Chart. 85. Rest of Middle East and Africa Companion Diagnostics Market Value, by Indication, 2021-2030 (USD Billion)
Chart. 86. Rest of Middle East and Africa Companion Diagnostics Market Value, by End-User, 2021-2030 (USD Billion)
Chart. 87. Arup Laboratories: Financials
Chart. 88. Arup Laboratories: Products & Services
Chart. 89. Arup Laboratories: Recent Developments
Chart. 90. Roche Molecular Systems Inc.: Financials
Chart. 91. Roche Molecular Systems Inc.: Products & Services
Chart. 92. Roche Molecular Systems Inc.: Recent Developments
Chart. 93. Dako Inc.: Financials
Chart. 94. Dako Inc.: Products & Services
Chart. 95. Dako Inc.: Recent Developments
Chart. 96. Qiagen Ltd.: Financials
Chart. 97. Qiagen Ltd.: Products & Services
Chart. 98. Qiagen Ltd.: Recent Developments
Chart. 99. Biomérieux Inc.: Financials
Chart. 100. Biomérieux Inc.: Products & Services
Chart. 101. Biomérieux Inc.: Recent Developments
Chart. 102. Ventana Medical Systems Inc.: Financials
Chart. 103. Ventana Medical Systems Inc.: Products & Services
Chart. 104. Ventana Medical Systems Inc.: Recent Developments
Chart. 105. Abbott Molecular Inc.: Financials
Chart. 106. Abbott Molecular Inc.: Products & Services
Chart. 107. Abbott Molecular Inc.: Developments
Chart. 108. Myriad Genetics Inc.: Financials
Chart. 109. Myriad Genetics Inc.: Products & Services
Chart. 110. Myriad Genetics Inc.: Recent Developments
Chart. 111. Biogenex Laboratories, Inc.: Financials
Chart. 112. Biogenex Laboratories, Inc.: Products & Services
Chart. 113. Biogenex Laboratories, Inc.: Recent Developments
Chart. 114. Thermo Fisher Scientific Inc.: Financials
Chart. 115. Thermo Fisher Scientific Inc.: Products & Services
Chart. 116. Thermo Fisher Scientific Inc.: Recent Developments

Companies Mentioned

  • ARUP LABORATORIES
  • ROCHE MOLECULAR SYSTEMS INC.
  • DAKO INC.
  • QIAGEN LTD.
  • BIOMÉRIEUX INC.
  • VENTANA MEDICAL SYSTEMS INC.
  • ABBOTT MOLECULAR INC.
  • MYRIAD GENETICS INC.
  • BIOGENEX LABORATORIES INC.
  • THERMO FISHER SCIENTIFIC INC.,

Related Topics

Related Reports

Companion Diagnostics Market by Technology, Indication, End-user - Global Forecast 2025-2030 - Product Image

Companion Diagnostics Market by Technology, Indication, End-user - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Companion Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Companion Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Companion Diagnostics Market By Product (Assays, Kits, Reagents, System, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung, Colorectal Cancer, CVD, Infectious, Neurology), Sample Type (Tissue, Blood) & Region - Forecast to 2029 - Product Image

Companion Diagnostics Market By Product (Assays, Kits, Reagents, System, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung, Colorectal Cancer, CVD, Infectious, Neurology), Sample Type (Tissue, Blood) & Region - Forecast to 2029

  • Report
  • 349 Pages
  • Global
From
Companion Diagnostics Global Market Report 2024 - Product Image

Companion Diagnostics Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Companion Diagnostic Market Analysis & Forecast to 2024-2034 - Product Image

Companion Diagnostic Market Analysis & Forecast to 2024-2034

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.